Abbott Laboratories
ABL
Company Profile
Business description
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Contact
100 Abbott Park Road
Abbott ParkIL60064-6400
USAT: +1 224 667-6100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
115,000
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
stocks
Will Australia’s dwindling fuel supplies impact this share?
Australia’s petrol reserves have dropped from 60 to 35 days.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.60 | 54.10 | 0.61% |
| CAC 40 | 7,962.39 | 0.00 | 0.00% |
| DAX 40 | 23,168.08 | 130.81 | -0.56% |
| Dow JONES (US) | 46,669.88 | 165.21 | 0.36% |
| FTSE 100 | 10,436.29 | 71.50 | 0.69% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,996.34 | 117.16 | 0.54% |
| Nikkei 225 | 53,767.28 | 353.60 | 0.66% |
| NZX 50 Index | 13,077.49 | 175.34 | 1.36% |
| S&P 500 | 6,611.83 | 29.14 | 0.44% |
| S&P/ASX 200 | 8,780.60 | 50.30 | 0.58% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |